Home Categories API Vildagliptin (LAF-237)
A8360812

Vildagliptin (LAF-237) , ≥99% , 274901-16-5

CAS NO.:274901-16-5

Empirical Formula: C17H25N3O2

Molecular Weight: 303.4

MDL number: MFCD08275142

EINECS: 630-410-0

Pack Size Price Stock Quantity
10MG RMB39.20 In Stock
50MG RMB55.20 In Stock
1G RMB81.60 In Stock
5G RMB212.00 In Stock
25G RMB728.80 In Stock
100G RMB2516.80 In Stock
others     Enquire
Update time: 2022-07-08

PRODUCT Properties

Melting point: 153-155?C
alpha  -78.3° (c = 9.73 in methanol)
Boiling point: 531.3±50.0 °C(Predicted)
Density  1.27
Flash point: 275.1℃
storage temp.  Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
solubility  Soluble in DMSO (up to 45 mg/ml), in DMF (up to 20 mg/ml), or in Ethanol (up to 20 mg/ml).
form  solid
pka 15.05±0.40(Predicted)
color  White
Stability: Stable for 2 years from date of purchase as supplied. Solutions in DMSO, DMF, or ethanol may be stored at -20°C for up to 3 months
InChI InChI=1S/C17H25N3O2/c18-9-14-2-1-3-20(14)15(21)10-19-16-5-12-4-13(6-16)8-17(22,7-12)11-16/h12-14,19,22H,1-8,10-11H2/t12?,13?,14-,16?,17?/m0/s1
InChIKey SYOKIDBDQMKNDQ-XWTIBIIYSA-N
SMILES N1(C(CNC23CC4CC(CC(O)(C4)C2)C3)=O)CCC[C@H]1C#N
CAS DataBase Reference 274901-16-5(CAS DataBase Reference)

Description and Uses

Vildagliptin, a DPP-4 inhibitor, was launched for the oral treatment of type 2 diabetes. Vildagliptin is the second DPP-4 inhibitor to reach the market behind sitagliptin, which was introduced in 2006. DPP-4 inhibitors act by slowing the inactivation of incretins, which are endogenous peptides involved in the physiologic regulation of glucose homeostasis. When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase the synthesis and release of insulin from pancreatic βcells via intracellular signaling pathways involving cAMP. GLP-1 also lowers glucagon secretion from pancreatic α cells, which leads to reduced hepatic glucose production. However, although GLP-1 and GIP effectively lower blood glucose, they are short-lived as a result of rapid inactivation by the ubiquitous serine protease DPP-4. By inhibiting DPP-4, vildagliptin increases the concentration and duration of active incretin levels, which in turn results in increased insulin release and decreased glucagon levels in a glucose-dependent manner. Both vildagliptin and sitagliptin are potent, competitive, reversible inhibitors of DPP- 4 (IC50=3.5 and 18 nM, respectively), and they both show slow, tight-binding inhibition kinetics.

The major metabolite of Vildagliptin

Safety

Symbol(GHS) 
GHS07
Signal word  Warning
Hazard statements  H302-H315-H319-H332-H335
Precautionary statements  P261-P280-P305+P351+P338
Risk Statements  28-38-41-48
Safety Statements  24/25-26-28-36/37/39
RIDADR  3077
HS Code  29339900

RELATED PRODUCTS